Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meetingBoris Jülg, Bruce D. Walker, Daniel R. Kuritzkes et al.|The Lancet HIV|2019Cited by 206
“We Need to Deploy Them Very Thoughtfully and Carefully”: Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States—A Qualitative InquiryKarine Dubé, Joseph D. Tucker, David Evans et al.|AIDS Research and Human Retroviruses|2017Cited by 70
Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the USKarine Dubé, Sandra B. Greene, David Evans et al.|Journal of Virus Eradication|2017Cited by 67
'Well, It's the Risk of the Unknown… Right?': A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United StatesKarine Dubé, Sandra B. Greene, Jeff Taylor et al.|PLoS ONE|2017Cited by 66
A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruptionMichael J. Peluso, Karine Dubé, Lynda Dee et al.|Journal of Virus Eradication|2020Cited by 54